Quote:
faraifarai Monday, 05/22/17 08:33:33 AM
Re: G Bert post# 182777
Post # of 182786

Management has done an excellent job to bring three lead compounds into four phase 2 trials all delivering topline data in 2017. Actually, it's a fantastic job--and I can't find a team that has been so nimble (Brilacidin acquisition) and so thrifty in getting stuff done. When looking at the share price, it can't go unnoticed (at least not for us longs) how the likes of Mako, The Pump Stopper, AF and Rosen Law Firm have criminally orchestrated a take down. Yes, that's the OTC, but that's also criminal activity--would love to see some lawsuits filed. I mention this because it hasn't been a lack of scientific progress and advancement that has hurt CTIX, it's been the forces of evil--and evil loses will always lose to data and science in the end. Anyway, I digress. The share price is heading north again, to what I think is a true valuation pre-topline reveals for Brilacidin and Prurisol, $200-400M MC range. March march march we go to around $2-4.

June-December is an opportunity in the biotech world that is a complete rarity--a quadfecta of phase 2 topline results being unveiled. It's true what's said here--there's not a single company with so many major milestones happening so fast. not one.

I'm jealous of every investor who can enter at this price range. My average is higher, and I'm overweighted extremely on CTIX, but I think that bulge in CTIX holdings in my brokerage account is going to one day represent some serious coin.

9 days until June....marching ahead toward topline results. Does everyone have a ticket? This is superbowl-style milestones approaching into the summer...transformative milestones ahead that can overnight swing the share price 10x-25x.

at least that's my theory and i'm sticking to it...